Key result
Heart failure-derived extracellular vesicles show altered subpopulations and trigger pro-inflammatory responses in target cells.
Why the study?
Extracellular vesicles reflect the onset and severity of cardiac diseases and attract interest as potential liquid biopsies. This study aimed to characterize plasma EVs in HFrEF and HFpEF to investigate their biomarker potential and evaluate how EV protein cargo affects the inflammatory milieu in human monocytes and cardiomyocytes.
Case-Control (n=70)
Extracellular vesicles from heart failure patients—particularly those with HFpEF—exhibit reduced specific cellular subpopulations, carry thrombo-inflammatory and fibrotic proteins, and directly induce pro-inflammatory cytokine expression in human monocytes and cardiomyocytes.
HF plasma EVs may promote inflammation; leaves open their biomarker or therapeutic potential in prospective studies.
Introduction Heart failure (HF) is a clinical syndrome involving structural and/or functional cardiac abnormalities, classified as reduced (HFrEF) or preserved (HFpEF) based on the ejection fraction percentage of the left ventricle. As extracellular vesicles (EVs) reflect onset and severity of cardiac diseases, they attract interest as potential liquid biopsies. Aims of the present project were: 1) to characterize EVs in HFrEF and HFpEF to investigate their potential as biomarkers; 2) to evaluate how protein EV-cargo can affect the inflammatory milieu in human monocytes and cardiomyocytes. Methods The study included 39 HF patients (13 HFpEF and 26 HFrEF) and 31 volunteers (CTR). EVs were isolated from plasma by size-exclusion chromatography and ultracentrifugation, in accordance with the latest ISEV guidelines (MISEV2023), then characterized using nanoparticles tracking analysis (NTA), transmission electron microscopy (TEM), Western blot (WB), flow cytometry (FACS) and proteomic analyses (targeted and untargeted). Functional assays were performed to assess the impact of patient-derived EVs on a cellular model of monocyte and cardiomyocytes. Results Diagnosis of HF relied on echocardiographic (e.g. E/e' ratio) and biochemical parameters (e.g. NT-proBNP). Isolation of EV was confirmed by FACS and WB analyses (CD63, CD9, CD81, Alix and β1 integrin), while integrity by TEM. Compared to CTR, no differences were found in terms EV size and concentration. Among the various EV subpopulations, vesicles originating from monocytes (CD14+), macrophages (CD206+), neutrophils (C66b+), activated endothelial cells (CD62E+), cardiomyocytes (CD172a), CD4+ T lymphocytes, and B lymphocytes (CD19+) were significantly reduced in HF by −58.2%, −82.3%, −25%, −40.3%, −60.4%, −55.2%, and −63.3%, respectively—an effect predominantly driven by EVs from HFpEF patients. Proteomic analysis showed that EVs carried proteins associated with thrombo-inflammation and fibrosis (e.g., PAI-1, vWF, GDF-15, IL-6, and galectin-3). Treatment of human monocytes (THP-1) with HF-derived EVs induced higher expression of pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, and IL-8) compared with cells exposed to EVs from CTR subjects. In human cardiomyocytes (AC16), exposure to HF-derived EVs increased IL-1β expression. These effects were largely driven by EVs isolated from HFpEF patients. Summary/Conclusions EVs derived from HF patients exhibit a distinct profile that reflects the hemodynamic characteristics of the condition and possess proinflammatory properties.
No takes yet. Share an insight, caveat, or question.
Macchi et al. (2026) conducted a case-control in Heart failure (HFrEF and HFpEF) (n=70). Heart failure-derived plasma extracellular vesicles (EVs) vs. Healthy volunteer (control) plasma extracellular vesicles was evaluated on Characterization of plasma EV subpopulations and their pro-inflammatory effects on human monocytes and cardiomyocytes. Heart failure-derived plasma EVs showed reduced immune and cardiac vesicle subpopulations (by 25% to 82.3%) and induced pro-inflammatory cytokines in monocytes and cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: